Practical transferable recommendations to standardize the reporting of bone marrow disease were developed. RESULTS: To the authors' knowledge, the current study is the first to comprehensively present consensus criteria for the collection, analysis, and reporting of the percentage area of bone marrow parenchyma occupied by tumor cells in trephinebiopsies. The quantitative analysis of neuroblastoma content in bone marrow aspirates by immunocytology and reverse transcriptasequantitative polymerase chain reaction are revised. The inclusion of paired-like homeobox 2b (PHOX2B) for immunohistochemistry and reverse transcriptase-quantitative polymerase chain reaction is recommended. Recommendations for recording bone marrow response are provided. The authors endorse the quantitative assessment of neuroblastoma cell content in bilateral core needle biopsies-trephines and aspirates in all children with neuroblastoma, with the exception of infants, in whom the evaluation of aspirates alone is advised. It is interesting to note that 5% disease is accepted as an internationally achievable level for disease assessment. CONCLUSIONS: The quantitative assessment of neuroblastoma cells is recommended to provide data from which evidence-based numerical criteria for the reporting of bone marrow response can be realized. This is particularly important in the minimal disease setting and when neuroblastoma detection in bone marrow is intermittent, where clinical impact has yet to be validated. The wide adoption of these harmonized criteria will enhance the ability to compare outcomes from different trials and facilitate collaborative trial design.
INTRODUCTION
Neuroblastoma is the most common extracranial solid tumor diagnosed in children, and accounts for 10% to 15% of all cancer deaths within the first 15 years of life. Metastatic disease at the time of diagnosis is a powerful predictor of poor outcome and is used in the International Neuroblastoma Risk Group (INRG) staging system to select treatment for children at the time of diagnosis. 1, 2 Bone marrow is the most common site of infiltration in children presenting with metastatic disease at the time of diagnosis, 2 and is a frequent site of disease recurrence. 3, 4 The persistence of neuroblastoma disease in bone marrow is predictive of poor outcome, [5] [6] [7] and provides a means with which to assess disease response without having to wait for the development of greater tumor burden, [8] [9] [10] thus making it attractive as part of clinical response criteria.
Cytology of aspirates and histology of biopsies have been the gold standard with which to assess neuroblastoma disease in bone marrow for many years. 1, 2, 11 However, these methods have limited sensitivity when neuroblastoma contamination is <10%, and could seriously underestimate the prevalence of bone marrow infiltration. 3, 12 Significant improvements in the sensitivity and specificity of neuroblastoma cell detection in bone marrow aspirates have been made, such that it is now possible to unambiguously detect a single neuroblastoma cell among 1 million normal cells using immunocytology (IC) or reverse transcriptase-quantitative polymerase chain reaction (RTqPCR). 13 Furthermore, these quantitative methods have shown that the level of neuroblastoma cells detected by IC 5, 14 or RTqPCR [15] [16] [17] in bone marrow is predictive of outcome, thereby paving the way for their introduction into clinical practice. Although consensus criteria for the detection of neuroblastoma cells in bone marrow aspirates have been described previously, 13 to our knowledge there is no comparable published guidance regarding the evaluation of bone marrow biopsies. So that the definition of bone marrow response is consistent across international studies, an International Neuroblastoma Response Criteria Bone Marrow Working Group (INRC BMWG) was convened to define consensus criteria for the standardized detection and reporting of bone marrow biopsies, and to review the criteria for the analysis of aspirates, building on previous international experience and exploiting new knowledge.
MATERIALS AND METHODS
The INRC BMWG was assembled, with representation from Europe, North America, and Australia, as a component of the Neuroblastoma Clinical Trials Planning Meeting held in April 2012 in Washington DC, supported by the National Cancer Institute. Experts from the INRC BMWG, representing the International Society of Pediatric Oncology Europe Neuroblastoma (SIOPEN) Group, the German Society of Pediatric Oncology and Hematology, the Children's Oncology Group, and the New Approaches to Neuroblastoma Therapy cooperative groups presented new data regarding neuroblastoma cell detection using immunohistochemistry (IHC), IC, and RTqPCR. Between January 2012 and September 2014, the INRC BMWG team of multidisciplinary experts in pediatric oncology, pathology, translational biology, and statistical methods reviewed the literature and shared, sought, and examined unpublished data and opinions, participating in >35 teleconference calls.
Recommendations for the Analysis and Reporting of Neuroblastoma Status in Bone Marrow
Sample collection and preparation for analysis and storage Bone marrow samples from at least 2 different sites should be analyzed, usually from the right and left iliac crest. 13, 18 We recommend the collection of representative bilateral core needle biopsies for histology/IHC and bilateral bone marrow aspirates for cytology, IC, and RTqPCR from all children at the time of diagnosis, and for high-risk children at the time of response assessment at the end of induction therapy; additional time points may be specified according to trial-specific protocols. We advocate the analysis of biopsies and aspirates in which disease infiltration is 5% by central reference laboratories. In very young or small infants, core needle biopsies are not recommended because the size and quality of the biopsy is unlikely to be adequate for robust analysis. When feasible, we suggest that the histology/IHC of bone marrow biopsies and cytology, IC, or RTqPCR of bone marrow aspirates are provided in a combined report so that any concordance or discordance is revealed.
Bone marrow aspirations from different sites should be performed using separate syringes, and aspirates should not be pooled so that the heterogeneity of neuroblastoma cell infiltration can be recorded and to avoid underestimating the extent of bone marrow disease. From the first aspiration (0.1-0.3 mL), approximately 5 to 10 smears of aspirate from each site should be prepared, air-dried, and stained using Pappenheim or modified Wright stain for initial staging using cytological examination by light microscopy. From the next 3 to 5 mL of each sample, 0.5 mL of each aspirate should be transferred immediately into RNA-preserving tubes such as PAXgene TM blood RNA tubes (Qiagen, Venlo, The Netherlands) for the extraction of RNA and RTqPCR. Samples in PAXgene TM blood RNA tubes can be stored at 2808C for up to 5 years or at room temperature for up to 3 days before RNA extraction. 17 The remaining aspirate is transferred into anticoagulant such as ethylenediaminetetraacetic acid (EDTA) or heparin, and cells are isolated using density gradient centrifugation for cytospin preparations for IC; Review Article cytospin preparations should be prepared within 24 hours of aspirate collection (maintained at 48C to 88C), and can be stored at 2208C until analyzed. 13 Bone marrow core needle biopsies should be placed immediately in fixative and decalcified. We recommend fixation in 4% buffered formalin for 18 to 24 hours, and decalcification by incubating in 12.5% EDTA at a pH of 7.0 for 4 to 6 hours to preserve morphology and antigenicity. The fixed, decalcified biopsy should be embedded in paraffin, and a minimum of 5 slides mounted with 2 to 3 sections of 4 lm prepared. A minimum of 2 slides should be stained with hematoxylin and eosin for histology, and the remaining unstained slides can be used for IHC, which is recommended.
Bone marrow quality
Only bone marrow samples of suitable quality should be investigated for diagnostic and prognostic purposes. If the sample is inadequate, we recommend a repeat aspiration or biopsy and reanalysis.
A bone marrow smear is considered representative and suitable for the quantitative reporting of disease when there is >5% tumor cell infiltration. When infiltration with tumor is 5%, then 3 of the following 4 criteria must be fulfilled to allow discrimination between no disease or minimal disease: 1) the presence of particles with stromal cells (eg, histiocytes, fibroblasts, or osteoblasts); 2) the presence of megakaryocytes; 3) erythroblasts are >20% of the nucleated cells; and 4) peripheral blood cells are within the range for age (ie, the mature granulocytes and lymphocytes do not exceed 65% in infants [those aged <1 year] or 50% in children [those aged >1 year]). If these criteria are not met, this should be detailed when reporting on analysis of the smear.
Cytospin preparations are prepared from mononuclear cells (MNCs) of the bone marrow and therefore rarely contain histiocytes and fibroblasts. Macrophages, granulocytes, megakaryocytes, and erythroblasts may be maintained in the MNC fraction at levels that are variable and always lower than in a bone marrow smear. It is interesting to note that erythroblasts never exceed 20% of all nucleated cells in a representative cytospin preparation. Therefore, the above-listed quality criteria for bone marrow smears do not apply to bone marrow cytospin preparations.
The routine aspiration of larger volumes is not recommended to avoid the dilution of the bone marrow with blood, which will reduce the sensitivity of analyses. Cells with disrupted cellular or nuclear membranes should not be analyzed.
For RTqPCR, each aspirate should yield a minimum of 400 ng of RNA, which has an optical density reading A 260 /A 280 ratio (ratio of absorbance at 260 nm vs 280 nm) of >1.5 and <3. Amplification of cDNA, generated from 100 ng of RNA, for a housekeeping gene such as b 2-microglobulin should produce a cycle threshold (Ct) <25. When there is insufficient aspirate to complete all analyses, the priority for investigations is cytology, followed by RTqPCR and finally IC.
An optimal bone marrow core needle biopsy preferably should contain red bone marrow parenchyma at a minimum length of 1 cm. This recommendation is derived from previous published work 19 and has since been supported by longstanding experience. The amount of hematopoietic and tumor tissue within the biopsy should be recorded in mm; cortical bone, cartilage, soft tissue, blood clots, or areas that are crushed are excluded from the measurement.
Criteria for analysis and reporting of neuroblastoma cell infiltration in bone marrow core trephine biopsies Histology. Metastatic tumor infiltration in bone marrow biopsies is estimated as the surface area occupied by peripheral neuroblastic tumor, as a percentage of the evaluable bone marrow spaces on each biopsy (eg, 0%, 5%, >5% to <10%, 10% to <15%, 15% to <20%, 20% to <25%, 25% to <30% and so on). Total bone marrow spaces can include areas of metastatic neuroblastoma, fibrosis and necrosis, hematopoietic components, and adipose tissue. The mitosis-karyorrhexis index should not be attempted because this is usually not feasible, reflecting the limited number of metastatic neuroblastoma cells in bone marrow biopsy specimens. 20 Importantly, tumor histology should be classified as poorly differentiated, undifferentiated, or differentiating. 20 In the case of small tumor aggregates, the presence or absence of neuropil (a complex network of interwoven cytoplasmic processes of neuroblasts) detected by IHC for synaptophysin can help to discriminate undifferentiated and poorly differentiated neuroblastoma. In those rare cases in which stroma-rich and stroma-poor histology are present within a single biopsy, the amount of stroma-rich and stroma-poor tumor should be recorded separately as a percentage of the surface area occupied by the tumor (Fig. 1 ).
Immunohistochemistry. IHC is frequently used to improve the precision of neuroblastoma detection in bone marrow biopsies. We encourage IHC of multiple sections (>3 sections) from all biopsies using a minimum of 2 antibodies; to minimize cost, 3 sections might be placed on a single slide with each antibody. Highly specific target antigens for which IHC is unambiguous include synaptophysin, tyrosine hydroxylase, chromogranin A, and paired-like homeobox 2b (PHOX2B). Additional frequently used markers include CD56 and PGP9.5.
11,20-24 When suspected, Schwann cells can be reliably detected by morphology and IHC for the S-100 protein. 20 Less useful markers for the detection of neuroblastoma cells in the bone marrow are neuron-specific enolase (NSE) and NB84, neuronspecific enolase because it lacks specificity 25 and NB84 because it is rarely expressed by neuroblastoma cells in the bone marrow. 26 The quality of any immunohistological analysis should be monitored by simultaneous processing of a positive control sample. Relevant controls can be sections from multi-tissue blocks including the adrenal gland or other neuroendocrine tissues; an ideal control would have areas of positive and negative cells.
A bone marrow biopsy is regarded as negative for tumor in the absence of neuroblastoma cell nests detected by hematoxylin and eosin staining and IHC, using a minimum of 2 antibodies to analyze at least 3 sections. A case should only be confirmed as negative after the assessment of all available sections.
Criteria for analysis and reporting of neuroblastoma cells in bone marrow aspirates Cytomorphology: bone marrow smears. Smears should be viewed by light microscopy at low (eg, 360-3100) and high (eg, 3600-31000) magnification. A low magnification is used to assess cellular density and search for the presence of large tumor cell nests or clumps, and a higher magnification to identify small tumor cell nests or any potential single neuroblastoma cells and to recognize features of differentiation. Neuroblastoma nests may contain Homer Wright rosettes, with neuroblastoma cells in a characteristic ring around a center of neuropil.
Neuroblastoma cells typically are round and larger than small lymphocytes, with a high nuclear:cytoplasmic ratio. The cell nucleus can be round or oval, with a fine granular chromatin structure (so-called "salt-andpepper" pattern) (Fig. 2) . This is not always present, and therefore it is not obligatory for the description of neuroblastoma. Cells in nests may range in size from large to intermediate to small, and can be polygonal in shape, producing a so-called "paving stone pattern." A nest or clump of typical neuroblasts is regarded as the lower threshold for reporting; a nest or clump contains at least 3 neuroblastoma cells (Fig. 2) . Granules are not visible, although in exceptional circumstances emperipolesis, phagocytosis, or inclusion bodies may be detected in neuroblastic cells. Although a rare event, neuroblastoma cells may mature spontaneously or after therapy (Fig. 2) ; if features of differentiation are detected in >5% of tumor cells this should be reported as the "presence of differentiating neuroblastoma cells." Single neuroblasts detected by cytology alone cannot unequivocally be identified as neuroblastoma cells, and should not be reported as such. The evaluated cellularity per slide should be reported because this can impact on the sensitivity of cytology. 27 Single cells alone should not be scored as positive; rather, we recommend such samples be reported as suspicious and the presence of neuroblastoma cells be confirmed or refuted after central review and analysis by additional methods such as IC. When no tumor cells are revealed, this should be recorded as a tumor cell-negative bone marrow aspirate.
IC cytospin preparation. Ideally, to reach a sensitivity of 1 neuroblastoma cell in 1310 6 MNCs, IC should be reported on 3310 6 MNCs per aspirate 27 using a monoclonal anti-GD 2 disialoganglioside antibody. We endorse the use of clone 14 G2a. 13 Bound antibody can be visualized by light microscopy after enzymatic reaction to produce a stable chromogen, or immunofluorescence when a fluorescent antibody or reporter is used. Criteria for the reliable light microscopic identification of neuroblastoma cells on immunocytochemically stained slides are published elsewhere and summarized in Table 1 . 13 When immunofluorescence is used, we recommend that digital images of positive cells with image acquisition details are stored because the fluorescence will fade with time. Cytospin preparations of control GD 2 -positive cells must be processed in parallel with the test samples to manage any interassay variation; these might usefully be bone marrow smears with a moderate to high tumor cell infiltration or cytospin preparations of a neuroblastoma cell line that contains high GD 2 -expressing and low GD 2 -expressing cells such as IMR-32. The number of tumor cells and the total number of investigated cells should be reported, from which the percentage of tumor infiltration can be calculated.
Reverse transcriptase-quantitative polymerase chain reaction
We recommend that RNA extracted from bone marrow aspirates taken at diagnosis be amplified by RTqPCR for the expression of at least the neuroblastoma mRNAs tyrosine hydroxylase and PHOX2B. 9, 16, 17 This is most strongly recommended within the minimal disease setting, in which neuroblastoma bone marrow contamination is 5% and the heterogeneity of the tumor content may have greatest impact. It is highly recommended for children with newly diagnosed, high-risk disease at the time of entry into trial and at times of response assessment (eg, at the end of induction treatment).
RNA ideally should be diluted to a minimum concentration of 40 ng/lL and stored in single-use aliquots (such as 10 lL) in a 2808C freezer. We recommend analysis of each RNA sample in triplicate, with each replicate containing 100 ng of RNA; the amount of RNA analyzed should be stated in the report. The results of RTqPCR must be reported as the Ct values so that any discrepancies between biological repeats can be identified, and using 2 2DCt or 2DCt, in which the expression of the neuroblastoma mRNAs is normalized to the internal control (in this case b 2-microglobulin): DCt 5 (Ct of neuroblastoma mRNA-Ct of b 2-microglobulin). The lower Ct for reporting RTqPCR for the neuroblastoma mRNAs is a Ct value of 40. A tumor-negative bone marrow has a Ct value of 40 for all of the neuroblastoma mRNAs examined, when amplification of the reference housekeeping gene generates a Ct value of <25. The quality of the amplification curves should be confirmed. [28] [29] [30] When possible, we strongly recommend reporting results using the comparative Ct method, also known as the 2 2DDCt method, 31, 32 which reports the fold change in DCt expression of the sample compared with a calibrator sample that is analyzed in each assay (ideally on each plate) to control for variation in amplification across different platforms. We advise that the sensitivity and specificity of RTqPCR analyses across centers analyzing samples from within clinical trials be maintained by quality control to minimize interlaboratory variability. 17 
Recommendations for Reporting Bone Marrow Response
Currently, we recommend >5% bone marrow infiltration as the internationally attainable level of reliable tumor detection for reporting bone marrow response (Table 2) . Importantly, prospectively, the number of neuroblastoma cells and level of neuroblastoma mRNAs in bilateral bone marrow aspirates and the percentage of tumor in bilateral bone marrow biopsies should be recorded to accumulate the data from which more precise evidence-based response criteria can be defined in the future (Table 2 and Table 3 ). This is essential in the setting of minimal disease (when tumor cell infiltration is 5%), and when infiltration on reassessment is increased 2-fold to >5% but does not reach 20%. Quantitative assessment of bone marrow infiltration is also important to more precisely evaluate the potential clinical impact of intermittent neuroblastoma cell detection. Not involved and not evaluable are clearly defined (Tables 2 and 3) ; when bone marrow samples were not obtained, this should be recorded as "not done" (ND or ND PCR for IC and RTqPCR, respectively). In the case of discrepant results between analysis of multiple bone marrow aspirates and biopsies using any of the described tion of mRNA currently available. The RNA template is converted into complementary DNA (cDNA) using the reverse transcriptase enzyme. The cDNA is then used as a template for exponential amplification using PCR. b Cycle threshold (Ct) is the number of PCR cycles required for the product (fluorescent signal) of RTqPCR to cross a set threshold. Ct values are inversely proportional to the amount of nucleic acid (ie, the higher the Ct value, the lower the amount of nucleic acid). c DCt is the difference between the Ct value for the target mRNA (Ct1) of interest and the Ct value of the reference mRNA sequence (Ct2; usually a house keeping gene). DCt 5 Ct1-Ct2. d Housekeeping genes are constitutively expressed at a relatively constant level in the tissues investigated under given assay conditions. e DDCt is the most frequently used method with which to report RTqPCR data. It is a relative quantification method in which the expression of a target transcript of interest (DCt1) is expressed relative to a constant reference sample (DCt2). DDCt 5 DCt12DCt2. methods, the sampled site with the highest level of tumor should be used to grade response. Where quantification is not possible locally and for the assessment of response in early phase 1 and 2 clinical trials, it is recommended that aspirates and biopsies are collected and analyzed by trialled central review.
DISCUSSION
To the best of our knowledge, the current study is the first to describe international consensus criteria for the collection, processing, and quantitative reporting of neuroblastoma cells in bone marrow biopsies. It is important to note that in biopsies we recommend reporting the percentage area of bone marrow parenchyma occupied by tumor cells to minimize errors that may arise when the number of tumor cells in a biopsy is very low (eg, after chemotherapy). We have developed these recommendations with the goal that they will be suitable for adoption across all centers treating children with neuroblastoma (Table 4) . We anticipate that, coupled with the updated guidance for the assessment of neuroblastoma cell contamination in bone marrow aspirates, they will facilitate a robust international standardization of bone marrow reporting. Previous studies have reported on the variation and inadequacy of bone marrow biopsy quality, 19, 33 underlining the need for change, which we anticipate the Consensus recommendations for the analysis of bone marrow trephine-biopsies/trephines and aspirates. Analysis of both bilateral bone marrow biopsies and aspirates is recommended. Immunohistochemistry of multiple sections using antibodies against 2 of the recommended antigens is advised and the inclusion of paired-like homeobox 2b (PHOX2B) is advocated. For immunocytology, we support the analysis of at least 3 3 10 6 mononuclear cells per aspirate using a monoclonal anti-GD 2 disialoganglioside antibody ; a second antibody may be included to control for those rare situations in which GD 2 expression is weak or negative. Within clinical trials, reverse transcriptase-quantitative polymerase chain reaction (RTqPCR) of RNA extracted from bone marrow aspirates is recommended to quantify the level of the neuroblastoma mRNAs tyrosine hydroxylase and PHOX2B. The results of RTqPCR must be reported as the cycle threshold (Ct) value and using 2 -DCt or 2DCt, in which the expression of the neuroblastoma mRNAs is normalized to an internal control; we recommend b 2-microglobulin.
comprehensive recommendations provided herein will expedite.
In response to the increased sensitivity and specificity of methods with which to quantify clinically relevant neuroblastoma cells in bone marrow, we advocate that children with bone marrow disease 5% are considered in a separate response category of minimal disease. In the future, the adoption of quantitative reporting of neuroblastoma cell numbers and mRNA levels in prospective clinical trials will inform a more precise definition of what constitutes a response in the setting of minimal disease. This information in the long term may inform the timely introduction of emerging effective agents with which to treat bone marrow disease, with an anticipated improvement in outcome. The international adoption of these recommendations will facilitate cross-trial comparisons and increase opportunities for collaborative trial design and research, with the expectation that this will speed the advancement of new treatments to improve outcome for children with disseminated disease.
Several studies have reported a greater frequency of neuroblastoma identification in bone marrow biopsies compared with aspirates. 34, 35 However, there is substantial agreement that analysis of both should be performed for the most accurate interpretation of bone marrow disease. [35] [36] [37] This might be particularly important in the setting of minimal disease, when sequential monitoring of bone marrow disease and response evaluation may be more informative. 3, 6, 7 Therefore, we recommend that both bilateral bone marrow aspirates and biopsies are analyzed, and their clinical value compared prospectively to inform future practice. The value of IC and IHC are both dependent on the quality of the sample, and the specificity and sensitivity of the antibodies used. For IHC, we advise using antibodies against at least 2 of the recommended antigens, endorsing the use of synaptophysin and chromogranin A 12 and advocating the introduction of PHOX2B. 22, 23 For IC, we support the use of antibodies to GD 2, 13 and commend the inclusion of a second antibody (eg, anti-PHOX2B or anti-CD56) to control for those rare situations in which GD 2 expression may be weak or negative. 38, 39 We advocate the use of RTqPCR within clinical trials to quantify the level of the neuroblastoma mRNA tyrosine hydroxylase (the most widely evaluated mRNA target, and which has prognostic value in bone marrow 13 ) in all children in the minimal disease setting and in high-risk children at trial-specific disease assessment time points. In addition, we now recommend the adoption of RTqPCR for PHOX2B mRNA in clinical trials, because this is reported to be a highly specific marker for the detection of disseminating neuroblastoma cells 16 and, in combination with tyrosine hydroxylase, may allow for the identification of children with disease that is refractory to treatment (Fig. 3) . 9 Additional methods may serve to improve the sensitivity and specificity of quantitative bone marrow analysis and reporting using IC or RTqPCR, including automatic immunofluorescence plus fluorescence in situ hybridization 39 and assessment of the RNA integrity number, 40 respectively. However, the dependency of these tests on specialist equipment prohibits their inclusion as standard recommendations for the assessment of disease. Although flow cytometry has been used to quantify neuroblastoma cell content in bone marrow aspirates, a requirement to analyze large numbers of cells reduces the sensitivity of this approach, which is not recommended in the clinical setting. 41 Consensus methods to detect neuroblastoma cells and mRNA in bone marrow aspirates and biopsies have been described (Fig. 3) . The future challenge will be to empower centers to improve the quality of bone marrow collection from children with neuroblastoma, and to assess whether these recommendations have changed practice. The adoption of these consensus recommendations by the international community will enhance the comparison of results from clinical trials to expedite trial-led changes in response assessment to improve outcomes for children with neuroblastoma.
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